Clinical trial · Observational
Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma
Multiplex Analysis of Serum Biomarkers for Prediction Interferon Therapy Response in Melanoma Patients
NCT00897546CI-TRIAL-00027707completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer, and may help doctors learn how well patients will respond to treatment. PURPOSE: This laboratory study is looking at biomarkers to predict the response to interferon therapy in patients with melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Generation of a comprehensive multiplexed array of melanoma-associated serological markers
- timeFrame
- 1 month
- description
- Generation of a comprehensive multiplexed array of melanoma-associated serological markers
Secondary outcomes (2)
- measure
- Changes in the profile of serological markers induced by interferon-alfa 2b therapy
- timeFrame
- 1 month
- description
- Changes in the profile of serological markers induced by interferon-alfa 2b therapy
- measure
- Panels of serological markers with prognostic and predictive power for interferon-alfa 2b response
- timeFrame
- 1 month
- description
- Panels of serological markers with prognostic and predictive power for interferon-alfa 2b response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of melanoma OR healthy volunteer (control) PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
References
Publications (1)
- RESULTYurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15;13(8):2422-8. doi: 10.1158/1078-0432.CCR-06-1805. PMID 17438101